- API
Any substance that is represented for use in a drug and that, when used in the manufacturing, processing, or packaging ...
- Active Ingredient
Any component that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, ...
- CAS No.
Unique number assigned to a specific chemical (identified by its chemical name) by the American Chemical Society and ...
Dihydroartemisinin
Catalog No. | PI0046 |
---|---|
CAS No. | 81496-82-4 |
Molecular Formula | C15H24O5 |
Molecular Weight | 284.14 |
Purity | 98% HPLC |
Package | 25 kg/drum |
Botanical Source | Aertemiisia Annua L. |
Appearance | White powder |
Storage | Stored in cool and dry places, protected from direct sunlight and heat. |
Shelf Life | 2 years |
Note: This dihydroartemisinin can also be used as reference standards. You can find it under the category of Reference Substance at Herbalext.com. |
Safety Tips of Dihydroartemisinin
Handling of dihydroartemisinin should only be performed by personnel trained and familiar with handling of potent active pharmaceutical ingredients. Moderate to severe irritant to the skin and eyes.
Related Products
-
Catalog No.: PI0017
CAS No.: 88495-63-0
Molecular Weight: 384.43
Purity: 97% HPLC
Package: 25 kg/drum
Related Applications
Antibacterial and Anti-inflammatory
Antibiotics are medicines that kill microorganisms and cure bacterial infections. Conventional medicine has produced a number of antibiotics, which doctors prescribe for a variety of infectious conditions. There are also several herbs used as natural antibiotics that are considered antibacterial or antimicrobial. Some medicines not only have an anesthetization function but also have the ability to decrease swelling, alleviate pain, resist bacteria, diminish inflammation, disinfect and sterilize. Herbal extract possesses these activities with lower toxicities.
Related Researches
- 1. Inhibitory effect of dihydroartemisinin against phorbol ester-induced cyclooxygenase-2 expression in macrophages.
Kim HG, et al. Food Chem Toxicol 2013 Jun;56:93-9.
- 2. Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a two-panel, two-way, two-period, randomized trial.
Kakuda T, et al. HIV Med 2013 Feb 26.
- 3. Pharmacokinetic predictors for recurrent malaria after dihydroartemisinin-piperaquine treatment of uncomplicated malaria in ugandan infants.
Creek DJ, et al. J Infect Dis 2013 Jun;207(11):1646-54.
- 4. Synthesis and cytotoxicity of novel 10-substituted dihydroartemisinin derivatives containing N-arylphenyl-ethenesulfonamide groups.
Liu Y, et al. Molecules 2013 Mar 4;18(3):2864-77.
- 5. DHA regulates angiogenesis and improves the efficiency of CDDP for the treatment of lung carcinoma.
Zhang JL, et al. Microvasc Res 2013 May;87:14-24.
- 6. Malaria transmission after artemether-lumefantrine and dihydroartemisinin-piperaquine: a randomized trial.
Sawa P, et al. J Infect Dis 2013 Jun;207(11):1637-45.
- 7. Dihydroartemisinin induces radiosensitivity in cervical cancer cells by modulating cell cycle progression.
Luo J, et al. Saudi Med J 2013 Mar;34(3):254-60.
- 8. Prevalence of antifolate resistance mutations in Plasmodium falciparum isolates in Afghanistan.
Awab GR, et al. Malar J 2013 Mar 15;12:96.
- 9. The evaluation of CYP2B6 inhibition by artemisinin antimalarials in recombinant enzymes and human liver microsomes.
Ericsson T, et al. Drug Metab Lett 2013 Mar 18.
- 10. Plasmodium falciparum susceptibility to anti-malarial drugs in Dakar, Senegal, in 2010: an ex vivo and drug resistance molecular markers study.
Fall B, et al. Malar J 2013 Mar 20;12:107.